On May 6, BGI Genomics Co.,Ltd. announced that it will rapidly provide a comprehensive detection and screening program for children with acute hepatitis of unknown cause.

Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy

REarranged during Transfection (RET) gene fusion is one of the common oncogenic variants in non-small cell lung cancers (NSCLCs). However, few RET fusion-positive cases have partner intergenic-breakpoint fusions, in which the partner breakpoint localizes to intergenic regions.

DiaSorin said on Friday that its first quarter revenues rose 34 percent year over year.

Rady Children's Hospital-San Diego is preparing to launch a consortium aimed at making rapid whole-genome sequencing (rWGS) a standard of care for newborns.

Mindray started laying the foundation of the world's 4th largest manufacturing base. Runda actively invested in the construction of sampling stand for nucleic acid detection in Shanghai. Calibra accelerated the track of multi omics source innovation of clinical products

Illumina said after the close of the market on Thursday that its first quarter revenues rose 12 percent year over year.

The US Food and Drug Administration said on Wednesday it has issued de novo classification to Fujirebio Diagnostics' Lumipulse G β-Amyloid Ratio (1-42/1-40) test, allowing the company to market it as a tool for diagnosing Alzheimer's disease.

On April 20, Fapon Biotech Inc. and Guomao Health reached a strategic cooperation intention for IVD ecological open platform. The signing ceremony of cooperation between DIAN Diagnostics Group Co., Ltd. and Taizhou Enze Medical Center was held in Taizhou Hospital.

BioMérieux said on Wednesday that its BioFire Joint Infection (JI) Panel has received de novo authorization from the US Food and Drug Administration.

Abbott announced on Wednesday that its multiplex sexually transmitted infection panel has received clearance from the US Food and Drug Administration.

On April 28, YHLO (688575. SH) released its annual performance report for 2021. From January 1 to December 31, 2021, the company achieved an operating revenue of 1.178 billion CNY, a year-on-year increase of 17.91%, a net profit of 205 million CNY, a year-on-year decrease of 2.75%.

Thermo Fisher Scientific on Thursday morning reported a 19 percent increase in first quarter revenues, driven by growth in most of its business segments.

Pfizer and BioNTech have submitted an application for Emergency Use Authorization for a COVID-19 vaccine booster dose in young children.

Recently, the first 5G digital mobile hospital in China jointly built by Roche Diagnostics, GE Healthcare, Boao Yiling Medical Group and Yutong Group was officially delivered.